Stellenwert der Immunonkologie bei der Therapie des Urothelkarzinoms

Keyphrases

• Programmed Death-ligand 1 (PD-L1) 100%
• Immuno-oncology 100%
• Urothelial Cancer 100%
• Conventional Chemotherapy 66%
• Second-line Treatment 33%
• Clinical Trials 33%
• Monotherapy 33%
• Combination Treatment 33%
• Standard of Care 33%
• Survival Benefit 33%
• Cystectomy 33%
• Phase II Trial 33%
• Perioperative Care 33%
• German Guidelines 33%
• Pembrolizumab 33%
• Nivolumab 33%
• Atezolizumab 33%
• Complete Surgical Resection 33%
• Adjuvant Immunotherapy 33%
• Anti-PD-1 Antibody 33%
• Metastatic Urothelial Carcinoma 33%
• Invasive Urothelial Carcinoma 33%
• Vinflunine 33%
• CTLA-4 Inhibitors 33%
• PD-L1 Antibody 33%
• Nephroureterectomy 33%
• Metastatic Urothelial Cancer 33%

Medicine and Dentistry

• Programmed Death-Ligand 1 100%
• Urothelial Cancer 100%
• Transitional Cell Carcinoma 66%
• Clinical Trial 33%
• Monotherapy 33%
• Cystectomy 33%
• CTLA-4 33%
• Nivolumab 33%
• Nephroureterectomy 33%
• Atezolizumab 33%
• Vinflunine 33%
• Immunotherapy 33%
• Pembrolizumab 33%
• Surgery 33%